Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521586 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,116
- Enrollment target
NCT00521586 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,116 participants.
The verdict
NCT00521586, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,116 participants
- Enrollment target
Study Summary
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.
Interventions
- BIOLOGICAL 13 valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521586
The ClinicalTrials.gov registry entry for NCT00521586 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 13 valent pneumococcal conjugate vaccine is the first listed.
NCT00521586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521586 about?
NCT00521586 is a clinical study titled "Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine". This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), ...
What is the current status of trial NCT00521586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,116 participants. The study started on 2007-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00521586?
The interventions under investigation include: 13 valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00521586?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.